公开(公告)号：US10688330B2

公开(公告)日：2020-06-23

申请号：US15535050

申请日：2015-12-10

Applicant: Yeda Research and Development Co. Ltd. ,  University of Washington

Inventor： Dan S. Tawfik ,  Haim Leader ,  Yaacov Ashani ,  Izhack Cherny ,  Moshe Goldsmith ,  Per Jr. Greisen ,  Sagar D. Khare ,  Gustav Oberdorfer ,  David Baker ,  Sarel Fleishman ,  Adi Goldenzweig ,  Nidhi Aggarwal

IPC: C12N9/16 ,  A61P25/00 ,  A62D3/02 ,  A62D101/02 ,  A62D101/26

Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.

公开(公告)号：US11802141B2

公开(公告)日：2023-10-31

申请号：US17078319

申请日：2020-10-23

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Tamuka Chidyausiku ,  Enrique Marcos ,  Lucas Nivon ,  Gustav Oberdorfer ,  David Baker ,  Lauren Carter

IPC: C07K14/47 ,  C12N15/11 ,  C07K17/00

CPC classification number: C07K14/47 ,  C07K17/00 ,  C12N15/111

Abstract: Beta-sheet forming polypeptides at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-24 are disclosed, together with their use and methods for designing beta-sheet forming polypeptides.

公开(公告)号：US20190083836A1

公开(公告)日：2019-03-21

申请号：US15535050

申请日：2015-12-10

Applicant: Yeda Research and Development Co, Ltd ,  University of Washington

Inventor： Dan S. TAWFIK ,  Haim LEADER ,  Yaacov ASHANI ,  Izhack CHERNY ,  Moshe GOLDSMITH ,  Per Jr. GRIESEN ,  Sagar D KHARE ,  Gustav Oberdorfer ,  David Baker ,  Sarel Fleishman ,  Adi Goldenzweig ,  Nidhi Aggarwal

IPC: A62D3/02 ,  C12N9/16 ,  A61P25/00

CPC classification number: A62D3/02 ,  A61P25/00 ,  A62D2101/02 ,  A62D2101/26 ,  C12N9/16 ,  C12Y301/08001

Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.